BR112013023609A8 - Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida - Google Patents

Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida

Info

Publication number
BR112013023609A8
BR112013023609A8 BR112013023609A BR112013023609A BR112013023609A8 BR 112013023609 A8 BR112013023609 A8 BR 112013023609A8 BR 112013023609 A BR112013023609 A BR 112013023609A BR 112013023609 A BR112013023609 A BR 112013023609A BR 112013023609 A8 BR112013023609 A8 BR 112013023609A8
Authority
BR
Brazil
Prior art keywords
symptoms associated
interferon
titer
stepped
rapid
Prior art date
Application number
BR112013023609A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013023609A2 (pt
Inventor
Deykin Aaron
Original Assignee
Biogen Idec Inc
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Inc filed Critical Biogen Idec Inc
Publication of BR112013023609A2 publication Critical patent/BR112013023609A2/pt
Publication of BR112013023609A8 publication Critical patent/BR112013023609A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
BR112013023609A 2011-03-15 2012-03-15 Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida BR112013023609A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (2)

Publication Number Publication Date
BR112013023609A2 BR112013023609A2 (pt) 2016-12-06
BR112013023609A8 true BR112013023609A8 (pt) 2018-04-03

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023609A BR112013023609A8 (pt) 2011-03-15 2012-03-15 Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida

Country Status (25)

Country Link
US (6) US9198955B2 (enExample)
EP (1) EP2686002B1 (enExample)
JP (2) JP6279905B2 (enExample)
KR (1) KR102050339B1 (enExample)
CN (1) CN103702680A (enExample)
AU (1) AU2012229104B2 (enExample)
BR (1) BR112013023609A8 (enExample)
CA (1) CA2846786C (enExample)
CY (1) CY1120176T1 (enExample)
DK (1) DK2686002T3 (enExample)
EA (1) EA028448B1 (enExample)
ES (1) ES2666850T3 (enExample)
HR (1) HRP20180621T1 (enExample)
HU (1) HUE036931T2 (enExample)
IL (1) IL228425A (enExample)
LT (1) LT2686002T (enExample)
MX (1) MX359947B (enExample)
PL (1) PL2686002T3 (enExample)
PT (1) PT2686002T (enExample)
RS (1) RS57175B1 (enExample)
SG (1) SG193446A1 (enExample)
SI (1) SI2686002T1 (enExample)
SM (1) SMT201800221T1 (enExample)
WO (1) WO2012125809A1 (enExample)
ZA (1) ZA201306933B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279905B2 (ja) * 2011-03-15 2018-02-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 速い用量調節の漸増投与レジメンを用いた、インターフェロンの筋肉内投与に伴うインフルエンザ様症状を軽減するための方法
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
US11266344B2 (en) 2016-09-21 2022-03-08 Samsung Electronics Co., Ltd. Method for measuring skin condition and electronic device therefor
JP7729379B2 (ja) * 2020-09-30 2025-08-26 コーニンクレッカ フィリップス エヌ ヴェ 用量漸増を行うための方法及びシステム

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
SK284989B6 (sk) * 1996-12-24 2006-04-06 Biogen, Inc. Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
US8932265B2 (en) * 2003-01-30 2015-01-13 Becton, Dickinson And Company Holder with safety shield for a drug delivery device
AU2005249233B2 (en) * 2004-06-01 2010-10-07 Ares Trading S.A. Stabilized interferon liquid formulations
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
EP2120869A2 (en) 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
KR20120027031A (ko) * 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
JP6279905B2 (ja) * 2011-03-15 2018-02-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 速い用量調節の漸増投与レジメンを用いた、インターフェロンの筋肉内投与に伴うインフルエンザ様症状を軽減するための方法

Also Published As

Publication number Publication date
JP2018030847A (ja) 2018-03-01
US20160101157A1 (en) 2016-04-14
IL228425A0 (en) 2013-12-31
CA2846786C (en) 2022-05-17
EA201301024A1 (ru) 2014-03-31
US20200046804A1 (en) 2020-02-13
PT2686002T (pt) 2018-04-23
US10500254B2 (en) 2019-12-10
JP2014508174A (ja) 2014-04-03
AU2012229104A1 (en) 2013-10-03
KR102050339B1 (ko) 2019-11-29
JP6522069B2 (ja) 2019-05-29
EA028448B1 (ru) 2017-11-30
SMT201800221T1 (it) 2018-07-17
WO2012125809A1 (en) 2012-09-20
PL2686002T3 (pl) 2018-10-31
KR20140038383A (ko) 2014-03-28
MX2013010507A (es) 2014-04-30
BR112013023609A2 (pt) 2016-12-06
HRP20180621T1 (hr) 2018-07-27
US20250276042A1 (en) 2025-09-04
IL228425A (en) 2017-08-31
US9198955B2 (en) 2015-12-01
LT2686002T (lt) 2018-05-10
CA2846786A1 (en) 2012-09-20
EP2686002A1 (en) 2014-01-22
HUE036931T2 (hu) 2018-08-28
EP2686002B1 (en) 2018-01-24
US20220280610A1 (en) 2022-09-08
RS57175B1 (sr) 2018-07-31
SI2686002T1 (en) 2018-06-29
NZ712273A (en) 2016-09-30
CY1120176T1 (el) 2018-12-12
ES2666850T3 (es) 2018-05-08
US20120237479A1 (en) 2012-09-20
JP6279905B2 (ja) 2018-02-14
DK2686002T3 (en) 2018-04-30
CN103702680A (zh) 2014-04-02
NZ616536A (en) 2015-10-30
SG193446A1 (en) 2013-10-30
ZA201306933B (en) 2016-07-27
US20170360890A1 (en) 2017-12-21
AU2012229104B2 (en) 2017-03-16
MX359947B (es) 2018-10-17

Similar Documents

Publication Publication Date Title
BR112014012739A8 (pt) composições e métodos para o tratamento do vírus da hepatite c
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
BR112015022197A2 (pt) tratamento de cataplexia
BR112015023646A2 (pt) inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
BRPI0817396B8 (pt) composição farmacêutica para tratar deficiência de vitamina b¹²
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
MX2014005122A (es) Inhibidores de la recirculacion de acidos biliares para el tratamiento de hipercolemia y enfermedad hepatica colestasica.
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
WO2007135172A3 (en) Cladribine regimen for treating multiple sclerosis
JOP20130236B1 (ar) تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha
BR112014008036A2 (pt) tratamento de rinite
BR112015010396A2 (pt) terapia de combinação
BR112014004587A2 (pt) combinações sinérgicas de inibidores de pi3k- e de mek
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112013023609A8 (pt) Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida
PE20100264A1 (es) Metodos para utilizar composiciones de liberacion sostenida de aminopiridina
DOP2014000264A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
BR112015012497A2 (pt) combinações farmacêuticas
BR112014000889A2 (pt) tratamento para hipoxia
BR112021023372A2 (pt) Método para o tratamento do câncer com uma forma de dosagem oral de um receptor de inibidor-alfa de estrogênio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOGEN INC. (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25B Requested transfer of rights rejected

Owner name: BIOGEN INC. (GB)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870250008450 DE 31/01/2025, POIS O PEDIDO SE ENCONTRA COM A INSTANCIA ADMINISTRATIVA ENCERRADA COM O DESPACHO DE MANUTENCAO DO INDEFERIMENTO PUBLICADO NA RPI NO 2839, DE 03/06/2025.

B25H Request for change of headquarter rejected

Owner name: BIOGEN INC. (GB)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870250008423 DE 31/01/2025, POIS O PEDIDO SE ENCONTRA COM A INSTANCIA ADMINISTRATIVA ENCERRADA COM O DESPACHO DE MANUTENCAO DO INDEFERIMENTO PUBLICADO NA RPI NO 2839, DE 03/06/2025.